Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Toronto Dominion Bank

Toronto Dominion Bank trimmed its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 67,800 shares of the medical equipment provider’s stock after selling 947 shares during the quarter. Toronto Dominion Bank’s holdings in Zimmer Biomet were worth $7,162,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Stonebridge Financial Group LLC purchased a new position in Zimmer Biomet in the 4th quarter valued at $25,000. Accredited Wealth Management LLC purchased a new position in Zimmer Biomet in the 4th quarter valued at $36,000. Kentucky Trust Co purchased a new position in Zimmer Biomet in the 4th quarter valued at $39,000. OFI Invest Asset Management purchased a new position in Zimmer Biomet in the 4th quarter valued at $40,000. Finally, Dunhill Financial LLC grew its position in Zimmer Biomet by 86.6% in the 4th quarter. Dunhill Financial LLC now owns 444 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 206 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the business’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. The trade was a 14.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.39% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on ZBH. Truist Financial set a $101.00 price objective on shares of Zimmer Biomet in a research report on Tuesday, May 6th. Canaccord Genuity Group lowered their price objective on shares of Zimmer Biomet from $115.00 to $101.00 and set a “hold” rating on the stock in a research report on Monday, May 12th. Raymond James lowered their price objective on shares of Zimmer Biomet from $119.00 to $104.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 6th. Royal Bank of Canada decreased their target price on shares of Zimmer Biomet from $125.00 to $112.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 6th. Finally, JMP Securities decreased their target price on shares of Zimmer Biomet from $140.00 to $125.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 7th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $111.53.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $92.73 on Thursday. Zimmer Biomet Holdings, Inc. has a 52 week low of $89.92 and a 52 week high of $120.13. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The firm’s 50-day simple moving average is $102.65 and its 200 day simple moving average is $105.59. The firm has a market capitalization of $18.35 billion, a PE ratio of 20.84, a P/E/G ratio of 1.95 and a beta of 0.78.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The business had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. During the same period in the previous year, the firm earned $1.94 EPS. The business’s revenue for the quarter was up 1.1% compared to the same quarter last year. On average, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.04%. The ex-dividend date was Monday, March 31st. Zimmer Biomet’s payout ratio is 21.24%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.